Meiogenix
Meiogenix develops novel plant breeding technologies that accelerate genetic gain and advanced variety development through targeted recombination, enabling breeders to unlock natural genetic diversity that is inaccessible through conventional methods. The company's proprietary recombination platform addresses the limitation that approximately one-quarter of beneficial genes are inaccessible due to suppressed…
Funding snapshot
About
Meiogenix develops novel plant breeding technologies that accelerate genetic gain and advanced variety development through targeted recombination, enabling breeders to unlock natural genetic diversity that is inaccessible through conventional methods. The company's proprietary recombination platform addresses the limitation that approximately one-quarter of beneficial genes are inaccessible due to suppressed recombination in cold regions of the genome such as pericentromeric regions. Meiogenix has achieved a 10x increase in targeted recombination in corn, enabling faster trait introgression, linkage drag separation, complex trait combination, and access to deleterious alleles in cold zones. The company serves both specialty crops (tomato, fruits, vegetables) and major field crops (corn, rice, wheat, soybean) through large-scale technology licensing partnerships with license fees, milestones, and royalties. Founded in 2010 and headquartered in Paris, France with US operations in Durham, North Carolina, the company has raised approximately $13 million at the Series A stage.
Business model
Genomics > Applied Genomics > Agrigenomics,
Life Sciences Platforms and Tools > Research Services > Diversified,
Crop Tech > Farm Inputs > Plant Breeding > Technology Providers
Founders & team highlights
Serial Founder
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.